tradingkey.logo

Insulet Corp

PODD
View Detailed Chart

341.850USD

+0.070+0.02%
Market hours ETQuotes delayed by 15 min
24.06BMarket Cap
101.92P/E TTM

Insulet Corp

341.850

+0.070+0.02%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.02%

5 Days

-1.89%

1 Month

+8.26%

6 Months

+33.83%

Year to Date

+30.94%

1 Year

+46.17%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
1 / 207
Overall Ranking
22 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 26 analysts
Buy
Current Rating
356.580
Target Price
+4.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.71% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8993.48.
Fairly Valued
The company’s latest PE is 101.63, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.80M shares, decreasing 4.97% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 8.68M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Ticker SymbolPODD
CompanyInsulet Corp
CEOMs. Ashley Mcevoy
Websitehttps://www.omnipod.com
KeyAI